Charcot-Marie-Tooth disease type 1A (CMT1A) and hereditary neuropathy with liability to pressure palsies (HNPP):: Reliable detection of the CMT1A duplication and HNPP deletion using 8 microsatellite markers in 2 multiplex PCRs

被引:0
|
作者
Seeman, P
Mazanec, R
Zidar, J
Hrusáková, S
Ctvrtecková, M
Rautenstrauss, B
机构
[1] Charles Univ, Sch Med 2, Dept Child Neurol, Prague 15006 5, Czech Republic
[2] Charles Univ, Sch Med 2, Dept Neurol, Prague 15006 5, Czech Republic
[3] Univ Ljubljana, Med Ctr, Inst Child Neurophysiol, Ljubljana 61105, Slovenia
[4] Univ Erlangen Nurnberg, Dept Human Genet, D-91054 Erlangen, Germany
关键词
Charcot-Marie-Tooth type 1; hereditary neuropathy with liability to pressure palsies; hereditary motor and sensory neuropathies; microsatellite markers; multiplex PCR; fragment analysis;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Charcot-Marie-Tooth disease (CMT) and hereditary neuropathy with liability to pressure palsies (HNPP) are the most frequent inherited disorders of the peripheral nervous system. They are clinically and genetically heterogeneous. A submicroscopic tandem duplication of 1.5 Mb in chromosome 17p11.2-12 comprising the PMP22 gene is found in 70.7% of autosomal dominant Charcot-Marie-Tooth type 1 (CMT1) patients. A reciprocal deletion is found in 87.6% of HNPP patients. The size of the typical CMT1A duplication is too small for classical cytogenetics and the whole region including the CMT1A-REP elements is sometimes too complex for a single DNA analysis method. We present results of a multiplex PCR of 8 microsatellite markers with multicolour fluorescence primer labelling followed by fragment analysis on an ABI 310 Prism analyzer to simplify the diagnostic procedure. Results for 24 patients can be obtained within 24 h. This method was applied on 92 DNA samples of unrelated patients carrying a typical CMT1A duplication previously confirmed by two colour fluorescence ii situ hybridization (FISH, probe c132G8) and EcoRI/SacI Southern blotting (probe pLR7.8). Three alleles of three different sizes were clearly detected at least once in 88 of them (95.6%). Subsequently this analysis was applied on 312 Czech patients and revealed a CMT1A/HNPP rearrangement in 109 out of them.
引用
收藏
页码:421 / 426
页数:6
相关论文
共 50 条
  • [31] Quality of life in hereditary neuropathy with liability to pressure palsies is as impaired as in Charcot-Marie-Tooth disease type 1A
    Bjelica, Bogdan
    Peric, Stojan
    Bozovic, Ivo
    Jankovic, Milena
    Brankovic, Marija
    Palibrk, Aleksa
    Stojanovic, Vidosava Rakocevic
    ACTA NEUROLOGICA BELGICA, 2021, 121 (06) : 1481 - 1486
  • [32] A global analysis of the CMT1A locus: implications for the origin and susceptibility to Charcot-Marie-Tooth disease type 1A across populations
    Rodriguez Cruz, P.
    Alitsiou, A.
    Diagne, R.
    Lia-Baldini, A.
    Ghorab, K.
    Diop, A. Gallo
    Ndiaye, M.
    Beltran, S.
    Lao, O.
    NEUROMUSCULAR DISORDERS, 2024, 43
  • [33] Status of the pivotal phase III study of PXT3003 for Charcot-Marie-Tooth Type 1A disease (CMT1A)
    Goedkoop, Rene
    Attarian, Sharam
    Young, Peter
    Sevilla, Teresa
    Van Damme, Philip
    de Visser, Marianne
    Thomas, Florian
    Roberts, Mark
    Foucquier, Julie
    Boutalbi, Youcef
    Cohen, Daniel
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2018, 23 (04) : 319 - 319
  • [34] Tolerability and efficacy study of P2X7 inhibition in experimental Charcot-Marie-Tooth type 1A (CMT1A) neuropathy
    Sociali, Giovanna
    Visigalli, Davide
    Prukop, Thomas
    Cervellini, Ilaria
    Mannino, Elena
    Venturi, Consuelo
    Bruzzone, Santina
    Sereda, Michael W.
    Schenone, Angelo
    NEUROBIOLOGY OF DISEASE, 2016, 95 : 145 - 157
  • [35] LOCALIZATION OF A LOCUS FOR CHARCOT-MARIE-TOOTH NEUROPATHY TYPE-IA (CMT1A) TO CHROMOSOME-17
    MCALPINE, PJ
    FEASBY, TE
    HAHN, AF
    KOMARNICKI, L
    JAMES, S
    GUY, C
    DIXON, M
    QAYYUM, S
    WRIGHT, J
    COOPLAND, G
    LEWIS, M
    KAITA, H
    PHILIPPS, S
    WONG, P
    KOOPMAN, W
    COX, DW
    YEE, WC
    GENOMICS, 1990, 7 (03) : 408 - 415
  • [36] Screening of the 17p11.2-p12 region in a large cohort of patients with Charcot-Marie-Tooth (CMT) disease or hereditary neuropathy with liability to pressure palsies (HNPP)
    Kabzinska, D.
    Pierscinska, J.
    Kochanski, A.
    JOURNAL OF APPLIED GENETICS, 2009, 50 (03) : 283 - 288
  • [37] SPHINGO- AND PHOSPHO-LIPIDS METABOLISM IMPAIRMENT AS A POTENTIAL THERAPEUTIC TARGET IN CHARCOT-MARIE-TOOTH TYPE 1A (CMT1A) NEUROPATHY
    Capodivento, G.
    Visigalli, D.
    Basit, A.
    Pastore, V. P.
    Armirotti, A.
    Schenone, A.
    Nobbio, L.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2015, 20 : S5 - S5
  • [38] CHARCOT-MARIE-TOOTH 1A (CMT1A) AND IMPAIRED PATIENT MOBILITY: EXPRESSIONS, REMEDIES AND IMPACT ON QUALITY OF LIFE
    Moore, A.
    Moore, A.
    Aldrich, J.
    VALUE IN HEALTH, 2019, 22 : S346 - S347
  • [39] Charcot-Marie-Tooth disease type 1A and hereditary neuropathy with liability to pressure palsies: a SacI polymorphism in the proximal CMT1A-REP elements may lead to genetic misdiagnosis
    Christina Fuchs
    Thomas Liehr
    Sevinc Özbey
    Arif Ekici
    Holger Grehl
    B. Rautenstrauss
    Neurogenetics, 1998, 2 : 43 - 46
  • [40] CMTNS AND OTHER OUTCOME MEASURES IN CHARCOT-MARIE-TOOTH DISEASE TYPE 1A (CMT1A): DATA FROM THE TRIALS WITH ASCORBIC AACID (CMT-TRIAAL AND CMT-TRAUK)
    Pareyson, D.
    Schenone, A.
    Fabrizi, G. M.
    Santoro, L.
    Quattrone, A.
    Vita, G.
    Padua, L.
    Gemignani, F.
    Reilly, M. M.
    Solari, A.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2009, 14 : 21 - 22